iCo Therapeutics announces enrolment completion and clinical update on Phase II iDEAL study for the treatment of diabetic macular edema (DME)
iCo Therapeutics Inc (TSX-V: ICO), headquartered in Vancouver, Canada has announced completion of enrolment in the Phase II “iDEAL” study designed to evaluate the efficacy… Read More »iCo Therapeutics announces enrolment completion and clinical update on Phase II iDEAL study for the treatment of diabetic macular edema (DME)